Azacitidine (5-Azacytidine)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza

30 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Azacitidine (5-Azacytidine) has been cited by 30 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rJe|AvOS13MDFOwG0> MmexNVIuPzJiaB?= MoHabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2jiTFI3OTN|MkS2
Jurkat  NXL6bWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXywMlEuPTBizszN M2rVV|EzNTd{IHi= MlXrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MX:yOlE{OzJ2Nh?=
CA46 MVzGeY5kfGmxbjDBd5NigQ>? NVvOTVRxOjEEoNM1US=> Mn;LOFghcA>? NYjneHdOcW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u M1e1cFI3OTN|MkS2
Raji  M{nZdmZ2dmO2aX;uJGF{e2G7 MVyxOeKhyrWP MWG0PEBp M3HaNolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= M{KyZ|I3OTN|MkS2
Jurkat  MkO3SpVv[3Srb36gRZN{[Xl? MX[zMlXDqML3TR?= NFH0SZY1QCCq MULpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? MXKyOlE{OzJ2Nh?=
MDA-MB-231 MXHGeY5kfGmxbjDBd5NigQ>? M3u1VVEwOi53L{Wg{txO M136WlQ5KGh? NWDVUYw6\GWlcnXhd4V{KHSqZTDQWHBPOTJiZYjwdoV{e2mxbjDheEB1cGViY3;uZ4VzdnS{YYTpc44hd2ZiNdMg{txOKDR6wrDo MXiyOVgyPzJ{OR?=
MDA-MB-231 MUnGeY5kfGmxbjDBd5NigQ>? NH\zbVAyNzJwNT:1JO69VQ>? M3z4fVQ5KGh? MmjLbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiRT3jZYRp\XKrbjDtVm5CKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAzNjYEoN88UYZweiB2ONMgbC=> NILYZ|AzPThzN{KyPS=>
MDA-MB-231 NYfmcpdMTnWwY4Tpc44hSXO|YYm= NWPuXll2OS9{LkWvOUDPxE1? NFHZUHkzPC92ODDo M3O2c4lv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=> M4DuOlI2QDF5MkK5
MCF-7 NUDhXG5VTnWwY4Tpc44hSXO|YYm= NV7hXGJlOS9{LkWvOUDPxE1? MYSyOE81QCCq NH7T[ZBqdmO{ZXHz[ZMhWEGUUDDjcIVifmGpZdMg NITN[|MzPThzN{KyPS=>
MDA-MB-231  NU\1Ro5GTnWwY4Tpc44hSXO|YYm= MWOxM|IvPS93IN88US=> NVSwSo9WOjRxNEigbC=> NUHFfZllcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKG2rUl7BMVEzPCCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhPSEQvF2= MmjBNlU5OTd{Mkm=
A498 MVfGeY5kfGmxbjDBd5NigQ>? Mki0NVAhyrWP M2K2PVczKGh? MUXpcoR2[2W|IITo[UBCTEGPVGOxPEBo\W6nIHX4dJJme3Orb36= NGruTFIzPTV4OUC4Oi=>
CaKI-2 NW\TSmF5TnWwY4Tpc44hSXO|YYm= M1zyWlExKML3TR?= MoLLO|IhcA>? NXHXZYk3cW6mdXPld{B1cGViQVTBUXRUOThiZ3Xu[UBmgHC{ZYPzbY9v MVqyOVU3QTB6Nh?=
Ketr-3 NWXzSFNCTnWwY4Tpc44hSXO|YYm= NY\jPJRPOTBiwsXN M13ZdlczKGh? NIfjNYRqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> MnzxNlU2PjlyOE[=
A253 M{LqW2Z2dmO2aX;uJGF{e2G7 M4\3WlExKML3TR?= MXSwMVQh\A>? M4K4U4lv[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsJI9nKHSqZTDNN3LDqGGodHXyJFI1KGh? M3qwW|I2PDh3NUO2
A253 MkHxSpVv[3Srb36gRZN{[Xl? M{TNblExKML3TR?= NIjHd2I4OiCq MVnpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{ MluxNlU1QDV3M{[=
A253 M2qxZmZ2dmO2aX;uJGF{e2G7 NHnkelUyOCEEtV2= NHL4enExNTRiZB?= M3fZTZJm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=> MUWyOVQ5PTV|Nh?=
PC3 NVTrNHE2TnWwY4Tpc44hSXO|YYm= M4HJNlAvOiEQvF5CpC=> NYHGRmNEPCCm NYHkSJg2cW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> M3PkWVI2PDd5M{Sw
MCF7 MWnGeY5kfGmxbjDBd5NigQ>? M2naOlAvOyEQvF5CpC=> M{H5[FQh\A>? NFvHZVlqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2 M3fZNlI2PDd5M{Sw
PC3 NHHifHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3mWYpqOC5{IN88UeKh NVv5eZVxPCCm NEn1Um9l\WO{ZXHz[ZMhfGinIHPlcIwh\3Kxd4ToJJRwKDJyLkOlJINwdWKrbnXkJJdqfGhiR2PLNVI3 MoO3NlU1Pzd|NEC=
MCF7 MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;GbW94OC5|IN88UeKh MWG0JIQ> M2\yV4Rm[3KnYYPld{B1cGViY3XscEBoem:5dHigNlQvQCViY3;tZolv\WRid3n0bEBIW0tzMk[= M3vVUlI2PDd5M{Sw
BGC-823 MYnGeY5kfGmxbjDBd5NigQ>? MUi1xsDPxE1? MlfkO|IhcA>? MWPk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 NVXHeZVCOjV2N{W3N|M>
MKN28 NYrjN5lPTnWwY4Tpc44hSXO|YYm= NF;USI42yqEQvF2= NIrTXHY4OiCq NULXOpp{\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? NXnJU4t4OjV2N{W3N|M>
SGC-7901 NFjIXJpHfW6ldHnvckBCe3OjeR?= MXS1xsDPxE1? MojlO|IhcA>? M1fhRoRm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk> NX:yW|g5OjV2N{W3N|M>
MKN45 NXrUdo9[TnWwY4Tpc44hSXO|YYm= MlX2OeKh|ryP NHzzW2c4OiCq NF62VmZl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 NX;YRWdIOjV2N{W3N|M>
BGC-823 MYjGeY5kfGmxbjDBd5NigQ>? NFrzVm42yqEQvF2= NHTSeJg4OiCq MWjk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M130cVI2PDd3N{Oz
MKN28 NHzPPHpHfW6ldHnvckBCe3OjeR?= NV;KdJk{PcLizszN Mk\mO|IhcA>? MX7k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M2XNSlI2PDd3N{Oz
SGC-7901 M1T4TWZ2dmO2aX;uJGF{e2G7 MXi1xsDPxE1? Mn7ZO|IhcA>? M1nt[YRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm= MXiyOVQ4PTd|Mx?=
MKN45 NHKwVXdHfW6ldHnvckBCe3OjeR?= NXvjfW9mPcLizszN M{XBc|czKGh? MWDk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M3HafVI2PDd3N{Oz
HREC M3\OSmZ2dmO2aX;uJGF{e2G7 MlTZOU8yOMLizszN NYXEOVE3PDhiaB?= M1fBWIlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Ml7RNlU{PTJ5NEe=
HRPE NUfMN5RKTnWwY4Tpc44hSXO|YYm= MWO1M|ExyqEQvF2= M4PFNFQ5KGh? MYHpcoR2[2W|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVfiN|Y5OjV|NUK3OFc>
HREC MUTGeY5kfGmxbjDBd5NigQ>? M{HCTVUwOTEEoN88US=> MWC0PEBp M3S0d4Rwf25vcnXneYxifGW|IH;mJHZGT0ZuIFnDRW0uOSBqbn;0JJBzd3SnaX6gcIV3\WxiaX6gTHJRTSClZXzsd{ktKEmOLUJOtkBld3OnLXTldIVv\GWwdHz5 M2\WUVI2OzV{N{S3
HRPE MoLTSpVv[3Srb36gRZN{[Xl? MXy1M|ExyqEQvF2= NVHzU4NWPDhiaB?= MYTkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk> MlruNlU{PTJ5NEe=
MSCs MlfLSpVv[3Srb36gRZN{[Xl? NIq2bIcyOCEQvF2= NW\MNoQ1OjRiaB?= M{HzbpBzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36= MnHFNlU{PTF|OUW=
HL-60 MkjISpVv[3Srb36gRZN{[Xl? NETsS3M2KM7:TR?= M{fabVczKGh? M3nSc2ROW09? NU[3PFVle2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ|OEKg[ZhxemW|c3nvci=> MofWNlU{OTlyNEm=
MV4-11 M4TmT2Z2dmO2aX;uJGF{e2G7 M3jsT|Uh|ryP NFTYbnk4OiCq M3;Eb2ROW09? MVfzbYdvcW[rY3HueIx6KHWycnXneYxifGW|IGrOSlM5OiCneIDy[ZN{cW:w NH:wfFQzPTNzOUC0PS=>
A2780 NEjwfHZHfW6ldHnvckBCe3OjeR?= MX61JOK2VcLi Ml;1O{Bl MVXpcoNz\WG|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt MoLuNlUzQTl4OUS=
CP70 NIDhWpZHfW6ldHnvckBCe3OjeR?= NH3qcmg2KML3TdMg M3H6bVch\A>? MYTpcoNz\WG|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt M3XqTlI2Ojl7Nkm0
A2780 Mn3RSpVv[3Srb36gRZN{[Xl? MmHPOUDDvU4EoB?= MYO3JIQ> NYToWm1Wf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36= NGjSSmszPTJ7OU[5OC=>
CP70 NY\DW5VDTnWwY4Tpc44hSXO|YYm= M4LDT|UhyrWPwrC= NVWyfWJ7PyCm MUT3[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? MkL6NlUzQTl4OUS=
OCM3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\0U3AxNjVxMT:yJO69VQ>? MXW3JIQ> MUPEUXNQ M1XGOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1jkOlI2OTR4OUix
92.1 M1;rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LUfFAvPS9zL{Kg{txO M4n3OFch\A>? MmHiSG1UVw>? MkO3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MXyyOVE1Pjl6MR?=
OCM1 M164bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\OXlAvPS9zL{Kg{txO M1nZPFch\A>? MXHEUXNQ NH23flhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUKyOVE1Pjl6MR?=
OMM1 M2L3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjkNE42NzFxMjFOwG0> NX;ucZY3PyCm MmXJSG1UVw>? Mk\ObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MknZNlUyPDZ7OEG=
Mel 285 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWwMlUwOS9{IN88US=> Ml32O{Bl NYjCe45KTE2VTx?= M3Tsb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXKxO2ZDOjVzNE[5PFE>
Mel 290 NF3hWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX32OlFzOC53L{GvNkDPxE1? NIKyRlg4KGR? NHP1PHdFVVOR MlLHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NH7ldWczPTF2Nkm4NS=>
OCM3 M13KSmZ2dmO2aX;uJGF{e2G7 MnPINE42NzFizszN M1HkfFQ5KGh? M4nvTGROW09? MkD0[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? M4DZZlI2OTR4OUix
92.1 NFrmbZJHfW6ldHnvckBCe3OjeR?= Ml\PNE42NzFizszN M1fFbFQ5KGh? MYfEUXNQ MnLN[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MUeyOVE1Pjl6MR?=
OCM1 Ml3sSpVv[3Srb36gRZN{[Xl? M2Oy[VAvPS9zIN88US=> Mn76OFghcA>? NIe5[JpFVVOR MoLj[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NXnXT5dkOjVzNE[5PFE>
OMM1 MYDGeY5kfGmxbjDBd5NigQ>? NEPVUFUxNjVxMTFOwG0> NF\1OXc1QCCq NXvTRWRUTE2VTx?= MU\k[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 M{nzblI2OTR4OUix
Mel 285 NEfISpZHfW6ldHnvckBCe3OjeR?= M1yzbFAvPS9zIN88US=> MVq0PEBp M3zjb2ROW09? NFrheoRl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7 NVLaNXRxOjVzNE[5PFE>
Mel 290 M3HVfWZ2dmO2aX;uJGF{e2G7 Mn36NE42NzFizszN MlHROFghcA>? MUXEUXNQ M2OzfoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? NXHnOYpkOjVzNE[5PFE>
OCM3 MX7GeY5kfGmxbjDBd5NigQ>? M3TpfFAvPS9zIN88US=> M2jmelQ5KGh? NHO0R2tFVVOR MUPk[YNz\WG|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg MU[yOVE1Pjl6MR?=
Mel 290 MkPpSpVv[3Srb36gRZN{[Xl? M4nvbFAvPS9zIN88US=> MVi0PEBp MWPEUXNQ Mkfi[IVkemWjc3XzJIlvfmG|aX;uJIRwe2ViZHXw[Y5l\W62bIpCpC=> MVyyOVE1Pjl6MR?=
OMM1 M3vzU2Z2dmO2aX;uJGF{e2G7 MlrSNE42NzFizszN MV:0PEBp MonwSG1UVw>? M1rJXIRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA> Mm\lNlUyPDZ7OEG=
OCM1 MnXqR4VtdCCYaXHibYxqfHliQYPzZZk> M1:2V|AvPS9zIN88US=> NYe1[I9UPSCm NUfrUWlETE2VTx?= M1HUWYRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u NV3ETXE6OjVzNE[5PFE>
92.1 MnvER4VtdCCYaXHibYxqfHliQYPzZZk> MmS3NE42NzFizszN MmHLOUBl NVf2S5J3TE2VTx?= MV3k[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= NIT0So8zPTF2Nkm4NS=>
OCM1 M{fRPWZ2dmO2aX;uJGF{e2G7 M1LRelAvPS9zIN88US=> MUi0PEBp MnLISG1UVw>? NGn6fVhk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp NWi5VnVOOjVzNE[5PFE>
OCM3 NX3tcJdETnWwY4Tpc44hSXO|YYm= MlP0NE42NzFizszN NX7Scot7PDhiaB?= NELkbpJFVVOR MYfjZZV{\XNiZ3zvZoFtKESQQTDofZBwdWW2aInsZZRqd25iYYSgUE0yKHKncHXheEBtd2Or NWP0PJA5OjVzNE[5PFE>
92.1 MmXySpVv[3Srb36gRZN{[Xl? MmLONE42NzFizszN NF\rbWc1QCCq NYfITVNpTE2VTx?= NIr1c3Zk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp NFzwemwzPTF2Nkm4NS=>
IMR32 MYfGeY5kfGmxbjDBd5NigQ>? MYCzJO69VQ>? M1PKSFczKGh? MYXEUXNQ M1ezcolv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> MkXqNlUyODR6NUC=
IMR5-75 Mn3sSpVv[3Srb36gRZN{[Xl? NIfLfIY{KM7:TR?= NYLqS2VtPzJiaB?= M1ribmROW09? MmGzbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 MWSyOVExPDh3MB?=
Be(2)-C Mn;QSpVv[3Srb36gRZN{[Xl? MXSzJO69VQ>? M2nYXlczKGh? MVTEUXNQ MXLpcoR2[2W|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= MXWyOVExPDh3MB?=
Bxpc-3 NYnYTJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvYOWRnPS9zMDFOwG0> NV3MXplrOjRxNEivO|IhcA>? M2n4WIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKEK6cHOtN{Bk\WyuczDpckB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{cx?= MYSyOVA3OTd|MR?=
Bxpc-3 MoLjRZBweHSxc3nzJGF{e2G7 NHPIdmI2NzFyIN88US=> M3XWW|I1NzR6L{eyJIg> NVLC[5BHcW6mdXPld{BieG:ydH;zbZMhcW5idHnt[U0h[W6mIHPvcoNmem62cnH0bY9vKG2jbn7ldpM> MVqyOVA3OTd|MR?=
Bxpc-3 MXnGeY5kfGmxbjDBd5NigQ>? M3rZXVUwOTBizszN MX2yOE81QC95MjDo NXLtWFRq\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo NUHhZ5hWOjVyNkG3N|E>
Bxpc-3 NX3hTIRETnWwY4Tpc44hSXO|YYm= NU[0XW5vPS9zMDFOwG0> MXSyOE81QC95MjDo M1W0c4Rm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2= NHXGZ3QzPTB4MUezNS=>
Bxpc-3 M4T0S2Z2dmO2aX;uJGF{e2G7 MYW1M|ExKM7:TR?= NHL5cI8zPC92OD:3NkBp M2X2T4Rwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=> NILHblczPTB4MUezNS=>
HL-60 NVzieJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO2bm9ROS5yIN88US=> NVzY[Wc5PDhiaB?= MVjzbYdvcW[rY3HueIx6KGmwaHnibZR{KEiOLU[wJINmdGxiZ4Lve5RpyqB? M3zlS|I2ODVzMUG5
HL-60 NHHPSmhHfW6ldHnvckBCe3OjeR?= M13QO|EvOCEQvF2= M4H6OlQ5KGh? MXnpcoNz\WG|ZYOgdFIyX0GIMT;DTXAyyqCjbnSgZ4F{eGG|ZT2zJIV5eHKnc4Ppc47DqA>? MWqyOVA2OTFzOR?=
HL-60 NEXF[mtHfW6ldHnvckBCe3OjeR?= MUSxMlAh|ryP MXS0PEBp NIDvb2Rl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NX;EfWtwOjVyNUGxNVk>
HuTu-80  NHjvUnBHfW6ldHnvckBCe3OjeR?= NFfkc3gyNzVxMUCg{txO M1r4blQ5Nzd{IHi= MYDpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXHRT|BCOjR7MESwOlI>
Caco2  NFL2[HlHfW6ldHnvckBCe3OjeR?= MUexNEDPxE1? NXnT[INGPDhiaB?= MlzGbY5kemWjc3XzJG5RSzGOMTDlfJBz\XO|aX;u MXyyOFkxPDB4Mh?=
HepG2  NYe0UVNtTnWwY4Tpc44hSXO|YYm= MnfiNE0zPSEQvF2= NH3lZpozPCCq M4TyNYRm[3KnYYPld{B{fWK2aXzpd4lvN2uneHnuJJR6eGViOTCoVGNUUzlrIIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJk> MnrmNlQ5PTV4NE[=
HepG2  MmrUSpVv[3Srb36gRZN{[Xl? NFXNNWgxNTJ3IN88US=> MVKyOEBp M{jVZ4lv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB? MVmyOFg2PTZ2Nh?=
HepG2  MkT3SpVv[3Srb36gRZN{[Xl? MnnYNVAh|ryvwrC= NVPJVWRDOC1{NDDo NX34UFJD\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW|c3nvckBi\nSncjC2JIg> NV3LXoRvOjR6NUW2OFY>
HepG2  NFnpcVNHfW6ldHnvckBCe3OjeR?= NWHCW2tIOTBizszt NFXXRo0zPCCq NWHLOVhMeHKxbX;0[ZMh[3m2b4PvcIlkKG6ndYTyZYwhdGmyaXSgZYNkfW23bHH0bY9vKGmwZHXw[Y5l\W62bImgc4Yh\XixZ3Xuc5V{KGyrcH;wdo91\Wmwcx?= NGPRNIYzPDh3NU[0Oi=>
HepG2  NFrudZBHfW6ldHnvckBCe3OjeR?= Mo\jNVAh|ryv NHLWUowzPCCq M2\KUpBz\X[nboTzJHNTTUKSIIDyc4Nme3Orbne= MWOyOFg2PTZ2Nh?=
HC45  NXTveo9RTnWwY4Tpc44hSXO|YYm= NY\kelQ5PcL3TdMg NFnEcG41KGR? M{LPOJJm\HWlZYOgeIhmKG2ndHj5cIF1cW:wIHzleoVteyCxZjDXTWYyNCCSMU[sJGNZS0xzNDygUmtZOuLCk{OsJGNFUDFuIFzBUWEyNCCjbnSgR3RPVkJz M1\0S|I1PzZ{OEC5
CNDT2  MorjSpVv[3Srb36gRZN{[Xl? Mk\YOeK2VcLi MVu0JIQ> Mo[wdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? MnXINlQ4PjJ6MEm=
CNDT2  NGnWe4NHfW6ldHnvckBCe3OjeR?= MXy1xtVOyqB? MVm0JIQ> M4frUolv[3KnYYPld{Bo\W6nIHX4dJJme3Orb36gc4bDqFeLRkGsJHAyPixiQ1TINUzDqEyDTVGxMOKh[W6mwrDDWG5PSjF? MnPlNlQ4PjJ6MEm=
T-cells NEW0PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq1M|IxKM7:TR?= NUf6OodtOC12ODDo MoDLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NXnQd|h2OjR5NUeyPFM>
CD3+ T-cells MXLGeY5kfGmxbjDBd5NigQ>? M321TlUwOjBizszN NXvBcoZzPDhiaB?= M3rvT5VxemWpdXzheIV{KHBzNTDlfJBz\XO|aX;u MV6yOFc2PzJ6Mx?=
CD4+ T-cells NX\FV5JvTnWwY4Tpc44hSXO|YYm= NHPGeFg2NzJyIN88US=> MkXwOFghcA>? MUn1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= NHLwZ5gzPDd3N{K4Ny=>
CD8+ T-cells MUDGeY5kfGmxbjDBd5NigQ>? NFTTbVQ2NzJyIN88US=> NYLTdIpSPDhiaB?= MlOweZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= MUOyOFc2PzJ6Mx?=
CD3+ T-cells NXj0[ZM3TnWwY4Tpc44hSXO|YYm= MUe1M|IxKM7:TR?= MWW0PEBp M4HJWpVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKE[RWGCz NWnVTnZGOjR5NUeyPFM>
CD4+ T-cells MUDGeY5kfGmxbjDBd5NigQ>? M4Ltd|UwOjBizszN M1jQOlQ5KGh? MX71dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBHV1iSMx?= NXPTNG84OjR5NUeyPFM>
CD4+ T-cells MY\GeY5kfGmxbjDBd5NigQ>? M1n5OlUwOjBizszN NGn2PY01QCCq MXry[YR2[2W|IGTCSXQyyqCvUl7BJIV5eHKnc4Ppc44> M33HWVI1PzV5Mkiz
CD4+ T-cells MUjGeY5kfGmxbjDBd5NigQ>? M4Dnc|UwOjBizszN M1vjTFQ5KGh? NITDN2R2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\sLiUl;S{tN1yqB? M{fMT|I1PzV5Mkiz
CD4+ T-cells NFnCfJJHfW6ldHnvckBCe3OjeR?= NF73d3Q2NzJyIN88US=> MYW0PEBp MlXObY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? MW[yOFc2PzJ6Mx?=
CD8+ T-cells Mlq2SpVv[3Srb36gRZN{[Xl? NH\Gd3Y2NzJyIN88US=> Mm\XOFghcA>? M37pc4lvcGmkaYTzJI1mdW:{eTDUMYNmdGy| NWfWWYtIOjR5NUeyPFM>
CD3+ T-cells M2LuTmZ2dmO2aX;uJGF{e2G7 NXH0R5NyPSEQvF2= MnXaOFghcA>? MlXzdoVlfWOnczDsc45oNXSncn2gcYVud3K7IHPlcIwheGinbn;0fZBm MmG5NlQ4PTd{OEO=
U937 NH2yUYFCeG:ydH;zbZMhSXO|YYm= NYTjfJJZOTBizszN MVO3NkBp NE\WVWNqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NEG5eZQzPDZ6MEi2OS=>
HL-60 MnfQRZBweHSxc3nzJGF{e2G7 NYC4[W55OTBizszN M13zb|czKGh? MV7pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NWTpdWZsOjR4OEC4OlU>
MCF7 NYr2bZhRTnWwY4Tpc44hSXO|YYm= M2\mNFUh|ryP M4PkRlQ5KGkEoB?= NYfTNYxV\Gm|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN? NGHKRZUzPDZ|M{O1NC=>
MCF7 NHLsUJBHfW6ldHnvckBCe3OjeR?= MW[xNEDPxE1? NUfh[|BiOjRiaNMg NGXKdnZqdmS3Y3XzJJRp\SClbHXheoFo\SCxZjDjZZNx[XOnIEegZY5lKFCDUmFCpC=> MVuyOFY{OzN3MB?=
MCF7 NYHsbGlITnWwY4Tpc44hSXO|YYm= NY\Beo9oOOLCk{CuOUDPxE4EoB?= MWG3JIQ> NGDB[lhqdmirYnn0d{B1cGViZ4Lve5RpKE2FRj23JJR2dW:{c4Do[ZJmeyCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzxsA> NYe4eHptOjR4M{OzOVA>
MCF7 M{HuVWZ2dmO2aX;uJGF{e2G7 NWf4eXhiOC53IN88UeKh NIm5c|YyPCCm NIOxb2tz\WS3Y3XzJJRp\SC|aYrlJI9nKE2FRj23JINwdG:waXXzJIVu[mWmZHXkJIlvKHOxZoSgZYdieg>? MWmyOFY{OzN3MB?=
MCF7 MWnGeY5kfGmxbjDBd5NigQ>? NYHPSHlWOC5yNfMAl|IxKM7:TR?= MkfCNUBl NXTKXmsxemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>? NVTwfYdOOjR4M{OzOVA>
T47D  MWHGeY5kfGmxbjDBd5NigQ>? NIrtfW0xNjVizszN MmfUOEBl NXfuOXVucW6qaXLpeJMhfHWvb4LzdIhmemViZn;ycYF1cW:w NWPOb|A2OjR4M{OzOVA>
MCF7 NHvodXlHfW6ldHnvckBCe3OjeR?= NGL6XHIxNjYkgKOxNEDPxE1? MorDOFghcMLi MnjobY5pcWKrdIOgeIhmKGejcDDjcI9{fXKnIHnuJJRp\SC5b4Xu[EBp\WGuaX7nJIF{e2G7 NYDLXmtZOjR4M{OzOVA>
MCF7 NFPBeZlHfW6ldHnvckBCe3OjeR?= M1PTbFAwOTBizszN NUH3XVBHOjRiaB?= M3j4WIlvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXA6 M320SlI1PjN|M{Ww
MDA-MB-231  MkPsSpVv[3Srb36gRZN{[Xl? NUPzSXRuOC534pETNVAh|ryP MoDnN|YhcA>? NUnTN3A3cW6qaXLpeJMhfGinIH3p[5JifGmxbh?= MoHmNlQ3OzN|NUC=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 ; 

PubMed: 28210112     


AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control.

c-PARP / p-H2AX / H2AX; 

PubMed: 28210112     


AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

28210112
Immunofluorescence
HMGB1 ; 

PubMed: 29097772     


U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒

29097772
Growth inhibition assay
Cell viability ; 

PubMed: 28210112     


AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

28210112
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
- Collapse
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms 5-AzaC,Ladakamycin, AZA,5-Aza
Smiles C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04172844 Recruiting Drug: Azacitidine|Drug: Venetoclax|Drug: Pevonedistat Acute Myelogenous Leukemia Ehab L Atallah|Medical College of Wisconsin January 13 2020 Phase 1
NCT04214860 Recruiting Drug: APR-246|Drug: Venetoclax|Drug: Azacitidine Myeloid Malignancy Aprea Therapeutics December 13 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) supplier | purchase Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) cost | Azacitidine (5-Azacytidine) manufacturer | order Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID